

Joshua D Rosenblat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4680745/publications.pdf>

Version: 2024-02-01

178
papers

8,725
citations

41258

49
h-index

58464

82
g-index

182
all docs

182
docs citations

182
times ranked

8855
citing authors

#	ARTICLE	IF	CITATIONS
1	Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2022, 101, 93-135.	2.0	670
2	Inflamed moods: A review of the interactions between inflammation and mood disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 53, 23-34.	2.5	468
3	Bipolar disorders. <i>Lancet, The</i> , 2020, 396, 1841-1856.	6.3	419
4	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021, 178, 383-399.	4.0	270
5	Stress, epigenetics and depression: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 102, 139-152.	2.9	246
6	Onset and frequency of depression in post-COVID-19 syndrome: A systematic review. <i>Journal of Psychiatric Research</i> , 2021, 144, 129-137.	1.5	214
7	Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review. <i>Journal of Affective Disorders</i> , 2018, 241, 519-532.	2.0	179
8	The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv082.	1.0	174
9	Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications. <i>Brain Sciences</i> , 2017, 7, 144.	1.1	162
10	Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countries. <i>Journal of Affective Disorders</i> , 2021, 290, 364-377.	2.0	159
11	The Effect of Loneliness on Distinct Health Outcomes: A Comprehensive Review and Meta-Analysis. <i>Psychiatry Research</i> , 2020, 294, 113514.	1.7	156
12	Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2016, 18, 89-101.	1.1	153
13	Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death. <i>JAMA Psychiatry</i> , 2021, 78, 1079.	6.0	151
14	Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. <i>Journal of Affective Disorders</i> , 2018, 227, 219-225.	2.0	135
15	Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression. <i>JAMA Psychiatry</i> , 2019, 76, 783.	6.0	135
16	Cognitive Deficits as a Mediator of Poor Occupational Function in Remitted Major Depressive Disorder Patients. <i>Clinical Psychopharmacology and Neuroscience</i> , 2016, 14, 1-16.	0.9	127
17	Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications. <i>Journal of Affective Disorders</i> , 2015, 188, 149-159.	2.0	126
18	Bipolar Disorder and Inflammation. <i>Psychiatric Clinics of North America</i> , 2016, 39, 125-137.	0.7	125

#	ARTICLE	IF	CITATIONS
19	The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. <i>Journal of Affective Disorders</i> , 2020, 276, 576-584.	2.0	118
20	The long-term effect of bariatric surgery on depression and anxiety. <i>Journal of Affective Disorders</i> , 2019, 246, 886-894.	2.0	117
21	Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder?. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 720-729.	1.1	115
22	Cannabidiol in medical marijuana: Research vistas and potential opportunities. <i>Pharmacological Research</i> , 2017, 121, 213-218.	3.1	102
23	Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 94, 11-16.	2.9	102
24	Mapping inflammation onto mood: Inflammatory mediators of anhedonia. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 64, 148-166.	2.9	97
25	Guidelines for the recognition and management of mixed depression. <i>CNS Spectrums</i> , 2017, 22, 203-219.	0.7	97
26	The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. <i>Journal of Affective Disorders</i> , 2018, 241, 484-491.	2.0	94
27	Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 109-117.	2.5	93
28	Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2018, 227, 406-415.	2.0	91
29	Probiotics for the treatment of depressive symptoms: An anti-inflammatory mechanism?. <i>Brain, Behavior, and Immunity</i> , 2018, 73, 115-124.	2.0	90
30	Medical comorbidity in bipolar disorder: The link with metabolic-inflammatory systems. <i>Journal of Affective Disorders</i> , 2017, 211, 99-106.	2.0	87
31	Are medical comorbid conditions of bipolar disorder due to immune dysfunction?. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 180-191.	2.2	84
32	Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 771.	1.2	80
33	APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. <i>Journal of Controlled Release</i> , 2011, 154, 298-305.	4.8	76
34	Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2467-2471.	2.2	76
35	The Mental Health Effects of COVID-19 on Health Care Providers in China. <i>American Journal of Psychiatry</i> , 2020, 177, 635-636.	4.0	76
36	Oral Ketamine for Depression. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	76

#	ARTICLE	IF	CITATIONS
37	Impact of SARS-CoV-2 Infection on Cognitive Function: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2020, 11, 621773.	1.3	74
38	Therapeutic Angiogenesis by Ultrasound-Mediated MicroRNA-126-3p Delivery. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2401-2411.	1.1	71
39	Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis. <i>Neuroscience Letters</i> , 2018, 686, 10-16.	1.0	70
40	The neural systems of emotion regulation and abnormalities in major depressive disorder. <i>Behavioural Brain Research</i> , 2019, 367, 181-188.	1.2	70
41	The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Affective Disorders</i> , 2020, 274, 903-910.	2.0	70
42	Drug-drug interactions as a result of co-administering Δ^9 -THC and CBD with other psychotropic agents. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 51-54.	1.0	64
43	A New Perspective on the Anti-Suicide Effects With Ketamine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 50-56.	0.7	60
44	Neurodevelopmental pathways in bipolar disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 112, 213-226.	2.9	59
45	The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2021, 134, 57-68.	1.5	58
46	The Efficacy of Psychostimulants in Major Depressive Episodes. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 412-418.	0.7	56
47	Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. <i>Journal of Affective Disorders</i> , 2019, 243, 116-120.	2.0	56
48	Targeting cytokines in reduction of depressive symptoms: A comprehensive review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 83, 86-91.	2.5	54
49	Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. <i>Journal of Psychiatric Research</i> , 2022, 151, 693-709.	1.5	52
50	The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 387-404.	2.5	51
51	Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review. <i>Current Neuropharmacology</i> , 2015, 13, 636-655.	1.4	50
52	The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 120, 78-85.	2.9	48
53	Registered clinical studies investigating psychedelic drugs for psychiatric disorders. <i>Journal of Psychiatric Research</i> , 2021, 139, 71-81.	1.5	47
54	Targeting the immune system in the treatment of bipolar disorder. <i>Psychopharmacology</i> , 2019, 236, 2909-2921.	1.5	45

#	ARTICLE	IF	CITATIONS
55	Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. <i>CNS Drugs</i> , 2022, 36, 17-30.	2.7	45
56	Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 631-639.	2.0	44
57	Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reduction. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 473-479.	1.1	43
58	Barriers, benefits and interventions for improving the delivery of telemental health services during the coronavirus disease 2019 pandemic: a systematic review. <i>Current Opinion in Psychiatry</i> , 2021, 34, 434-443.	3.1	42
59	Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research. <i>Infectious Diseases</i> , 2022, 54, 467-477.	1.4	42
60	The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. <i>Bipolar Disorders</i> , 2020, 22, 831-840.	1.1	40
61	The utility of smartphone-based, ecological momentary assessment for depressive symptoms. <i>Journal of Affective Disorders</i> , 2020, 274, 602-609.	2.0	40
62	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 222, 14-20.	2.0	39
63	Depressive disorders: Processes leading to neurogeneration and potential novel treatments. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 80, 189-204.	2.5	37
64	Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case-control study. <i>Amino Acids</i> , 2018, 50, 1013-1023.	1.2	36
65	Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression. <i>Cells</i> , 2020, 9, 895.	1.8	36
66	A Systematic review of the validity of screening depression through Facebook, Twitter, Instagram, and Snapchat. <i>Journal of Affective Disorders</i> , 2021, 286, 360-369.	2.0	36
67	Therapeutic potential of JAK/STAT pathway modulation in mood disorders. <i>Reviews in the Neurosciences</i> , 2018, 30, 1-7.	1.4	35
68	Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. <i>CNS Drugs</i> , 2021, 35, 925-934.	2.7	35
69	Evidence supporting a mechanistic role of sirtuins in mood and metabolic disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 86, 95-101.	2.5	34
70	Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 300, 449-461.	2.0	34
71	Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 1-7.	2.5	30
72	Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Affective Disorders</i> , 2020, 276, 570-575.	2.0	30

#	ARTICLE	IF	CITATIONS
73	Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 410-423.	1.3	29
74	The emerging role of psilocybin and MDMA in the treatment of mental illness. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1263-1273.	1.4	29
75	Predicting antidepressant response using early changes in cognition: A systematic review. <i>Behavioural Brain Research</i> , 2018, 353, 154-160.	1.2	28
76	The Association Between Adverse Childhood Experiences and Inflammation in Patients with Major Depressive Disorder: A Systematic Review. <i>Journal of Affective Disorders</i> , 2020, 272, 1-7.	2.0	28
77	Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. <i>Journal of Affective Disorders</i> , 2021, 293, 285-294.	2.0	28
78	Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. <i>Annals of Clinical Psychiatry</i> , 2018, 30, 38-50.	0.6	28
79	Prevalence of fibromyalgia and co-morbid bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2015, 188, 134-142.	2.0	27
80	Depression and Disturbed Bone Metabolism: A Narrative Review of the Epidemiological Findings and Postulated Mechanisms. <i>Current Molecular Medicine</i> , 2016, 16, 165-178.	0.6	27
81	Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin. <i>Journal of Psychiatric Research</i> , 2021, 133, 82-92.	1.5	27
82	Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 63-74.	1.0	27
83	Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review. <i>Journal of Psychiatric Research</i> , 2021, 137, 426-436.	1.5	27
84	Role of Proinflammatory Cytokines in Dopaminergic System Disturbances, Implications for Anhedonic Features of MDD. <i>Current Pharmaceutical Design</i> , 2017, 23, 2065-2072.	0.9	27
85	Assessing and measuring cognitive function in major depressive disorder. <i>Evidence-Based Mental Health</i> , 2016, 19, 106-109.	2.2	26
86	Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1031-1040.	1.0	25
87	The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review. <i>Journal of Psychiatric Research</i> , 2021, 137, 232-241.	1.5	25
88	Development and implementation of guidelines for the management of depression: a systematic review. <i>Bulletin of the World Health Organization</i> , 2020, 98, 683-697H.	1.5	25
89	Depression in the medically ill. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 346-366.	1.3	24
90	A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. <i>Journal of Affective Disorders</i> , 2021, 282, 160-164.	2.0	24

#	ARTICLE	IF	CITATIONS
91	Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 899-913.	0.6	24
92	Deficits of social cognition in bipolar disorder: Systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2022, 24, 137-148.	1.1	23
93	Synergistic effect of social media use and psychological distress on depression in China during the COVID-19 epidemic. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 552-554.	1.0	22
94	Registered clinical trials investigating ketamine for psychiatric disorders. <i>Journal of Psychiatric Research</i> , 2020, 127, 1-12.	1.5	22
95	Pharmacologic implications of inflammatory comorbidity in bipolar disorder. <i>Current Opinion in Pharmacology</i> , 2016, 29, 63-69.	1.7	21
96	Serum metabolic profiling using small molecular water-soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre-post-treatment design. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 100-108.	1.0	20
97	The abuse liability of ketamine: A scoping review of preclinical and clinical studies. <i>Journal of Psychiatric Research</i> , 2022, 151, 476-496.	1.5	20
98	Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment. <i>Psychopharmacology</i> , 2021, 238, 917-926.	1.5	19
99	Peripheral inflammatory biomarkers define biotypes of bipolar depression. <i>Molecular Psychiatry</i> , 2021, 26, 3395-3406.	4.1	19
100	Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression. <i>Advances in Therapy</i> , 2021, 38, 2795-2820.	1.3	19
101	The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits. <i>Psychopharmacology</i> , 2022, 239, 2011-2039.	1.5	19
102	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 1173-1182.	1.3	18
103	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. <i>CNS Spectrums</i> , 2019, 24, 154-162.	0.7	18
104	Pharmacogenomics of ketamine: A systematic review. <i>Journal of Psychiatric Research</i> , 2022, 145, 27-34.	1.5	18
105	The THINC-it Tool for Cognitive Assessment and Measurement in Major Depressive Disorder: Sensitivity to Change. <i>Frontiers in Psychiatry</i> , 2020, 11, 546.	1.3	17
106	The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE). <i>Psychiatry Research</i> , 2021, 302, 113993.	1.7	16
107	Trace elements differences in the depression sensitive and resilient rat models. <i>Biochemical and Biophysical Research Communications</i> , 2020, 529, 204-209.	1.0	15
108	Ecological momentary assessment of depressive symptoms using the mind.me application: Convergence with the Patient Health Questionnaire-9 (PHQ-9). <i>Journal of Psychiatric Research</i> , 2021, 135, 311-317.	1.5	15

#	ARTICLE	IF	CITATIONS
109	Trace amine-associated receptor 1 (TAAR1): Potential application in mood disorders: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 131, 192-210.	2.9	15
110	Treatment of mixed features in bipolar disorder. <i>CNS Spectrums</i> , 2017, 22, 141-146.	0.7	14
111	Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial. <i>Journal of Psychopharmacology</i> , 2019, 33, 1388-1394.	2.0	14
112	Immune response to vaccination in adults with mental disorders: A systematic review. <i>Journal of Affective Disorders</i> , 2022, 304, 66-77.	2.0	14
113	Treatment recommendations for DSM-5â€‘defined mixed features. <i>CNS Spectrums</i> , 2017, 22, 147-154.	0.7	13
114	The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 841-852.	1.0	13
115	Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 475-482.	1.5	12
116	Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 105, 110126.	2.5	12
117	Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it). <i>Scandinavian Journal of Pain</i> , 2017, 15, 62-67.	0.5	11
118	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2018, 238, 228-232.	2.0	11
119	Leptin mediates improvements in cognitive function following treatment with infliximab in adults with bipolar depression. <i>Psychoneuroendocrinology</i> , 2020, 120, 104779.	1.3	11
120	The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Psychopharmacology</i> , 2021, 35, 128-136.	2.0	11
121	Do sleep changes mediate the antiâ€‘depressive and antiâ€‘suicidal response of intravenous ketamine in treatmentâ€‘resistant depression?. <i>Journal of Sleep Research</i> , 2022, 31, e13400.	1.7	11
122	Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects. <i>Psychiatry Research</i> , 2021, 306, 114231.	1.7	11
123	Olanzapine and samidorphan combination treatment: A systematic review. <i>Journal of Affective Disorders</i> , 2022, 301, 99-106.	2.0	11
124	The influence of prescriber and patient gender on the prescription of benzodiazepines: evidence for stereotypes and biases?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 1083-1089.	1.6	10
125	Comparing mortality from covid-19 to mortality due to overdose: A micromort analysis. <i>Journal of Affective Disorders</i> , 2022, 296, 514-521.	2.0	10
126	The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. <i>Journal of Affective Disorders</i> , 2021, 294, 592-596.	2.0	10

#	ARTICLE	IF	CITATIONS
127	Major Depressive Disorder and Type II Diabetes Mellitus: Mechanisms Underlying Risk for Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 13, 1740-1749.	0.8	10
128	Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis. <i>CNS Spectrums</i> , 2021, , 1-9.	0.7	9
129	Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorder. <i>Journal of Affective Disorders</i> , 2021, 282, 448-453.	2.0	9
130	The impact of overweight/obesity on monetary reward processing: A systematic review. <i>Journal of Psychiatric Research</i> , 2021, 137, 456-464.	1.5	9
131	Letter to the Editor: Clinical versus statistical significance of pharmacogenomic-guided antidepressant therapy: What's really being measured and marketed?. <i>Journal of Psychiatric Research</i> , 2019, 114, 208-209.	1.5	8
132	Repetitive transcranial magnetic stimulation for cognitive function in adults with bipolar disorder: A pilot study. <i>Journal of Affective Disorders</i> , 2021, 293, 73-77.	2.0	8
133	Management of cognitive impairment in bipolar disorder: a systematic review of randomized controlled trials. <i>CNS Spectrums</i> , 2021, , 1-22.	0.7	8
134	Pharmacological Approaches to Minimizing Cardiometabolic Side Effects of Mood Stabilizing Medications. <i>Current Treatment Options in Psychiatry</i> , 2017, 4, 319-332.	0.7	7
135	Effects of infliximab on brain neurochemistry of adults with bipolar depression. <i>Journal of Affective Disorders</i> , 2021, 281, 61-66.	2.0	7
136	The Prevalence of Suicidal Behaviour in Fibromyalgia Patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 108, 110078.	2.5	7
137	Loneliness-based impaired reward system pathway: Theoretical and clinical analysis and application. <i>Psychiatry Research</i> , 2021, 298, 113800.	1.7	7
138	Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation. <i>CNS Spectrums</i> , 2022, 27, 315-321.	0.7	7
139	Factors That Impact Treatment Decisions. primary care companion for CNS disorders, The, 2018, 20, .	0.2	7
140	Frequency of use and perceived helpfulness of wellness strategies for bipolar and unipolar depression. <i>Annals of Clinical Psychiatry</i> , 2018, 30, 296-304.	0.6	7
141	Parental characteristics and the risk of schizophrenia in a Chinese population: a case-control study. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 90-95.	0.7	6
142	Association of history of adverse childhood experiences with irritable bowel syndrome (IBS) in individuals with mood disorders. <i>Psychiatry Research</i> , 2020, 288, 112967.	1.7	6
143	Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110032.	2.5	6
144	The influence of prescriber and patient gender on the prescription of benzodiazepines: results from the Florida Medicaid Dataset. <i>CNS Spectrums</i> , 2022, 27, 378-382.	0.7	6

#	ARTICLE	IF	CITATIONS
145	Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment. <i>Journal of Affective Disorders</i> , 2021, 288, 210-216.	2.0	6
146	Leptin, obesity, and response to ketamine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 98, 109773.	2.5	5
147	Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?. <i>Journal of Affective Disorders</i> , 2021, 292, 714-719.	2.0	5
148	Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic. <i>Psychiatry Research</i> , 2021, 303, 114086.	1.7	5
149	Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence. <i>CNS Spectrums</i> , 2022, 27, 322-330.	0.7	5
150	Frequency Analysis of Symptomatic Worsening Following Ketamine Infusions For Treatment Resistant Depression in a Real-World Sample: Results From the Canadian Rapid Treatment Centre of Excellence. <i>Psychiatry Research</i> , 2021, 307, 114321.	1.7	5
151	A review of potential neuropathological changes associated with ketamine. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 813-831.	1.0	5
152	Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review. <i>Psychiatry Research</i> , 2022, 312, 114579.	1.7	5
153	Deconstructing Diabetes and Depression: Clinical Context, Treatment Strategies, and New Directions. <i>Focus (American Psychiatric Publishing)</i> , 2016, 14, 184-193.	0.4	3
154	Dementia with Lewy bodies presenting as psychotic depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 1160-1161.	1.3	3
155	Inflammation in Bipolar Disorder. , 2018, , 445-454.		3
156	Trial of SAGE-217 in Patients with Major Depressive Disorder. <i>New England Journal of Medicine</i> , 2019, 381, 2178-2179.	13.9	3
157	Is ketamine a litmus test for capacity in assisted dying with depression?. <i>Psycho-Oncology</i> , 2021, 30, 417-420.	1.0	3
158	The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence. <i>Psychiatry Research</i> , 2021, 300, 113860.	1.7	3
159	Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. <i>Journal of Psychiatric Research</i> , 2021, 143, 209-214.	1.5	3
160	Potential differences in antidepressant effects of oral ketamine liquid suspension versus compounded capsules. <i>British Journal of Psychiatry</i> , 2019, 215, 434.	1.7	2
161	Pharmacological Treatment of Major Depressive Disorder. , 2020, , 103-119.		2
162	Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder. <i>Psychiatry Research</i> , 2020, 284, 112767.	1.7	2

#	ARTICLE	IF	CITATIONS
163	H1N1 FEAR RISING FOR WORKERS EVERYWHERE, BUT WILL THEY WEAR A MASK? IF NOT, WHY NOT?. Chest, 2009, 136, 47S.	0.4	1
164	Depression, Diabetes and Dementia. Key Issues in Mental Health, 2015, , 42-53.	0.6	1
165	Are Antidepressants Harmful in the "General Population"? Psychotherapy and Psychosomatics, 2018, 87, 179-179.	4.0	1
166	Letter to the editor: Inadequate evidence to support improved patient outcomes with combinatorial pharmacogenomics. Journal of Psychiatric Research, 2018, 107, 136-137.	1.5	1
167	Consumer Warning for Genetic Tests Claiming to Predict Response to Medications: Implications for Psychiatry. American Journal of Psychiatry, 2019, 176, 412-413.	4.0	1
168	Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. Journal of Psychiatric Research, 2021, 136, 444-451.	1.5	1
169	Drs Rosenblat and McIntyre Reply. Journal of Clinical Psychiatry, 2020, 81, .	1.1	1
170	Efficacy and Tolerability of Two Novel "Standard of Care" Treatments" Intranasal Esketamine Versus Intravenous Ketamine" for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study. JMIR Research Protocols, 2022, 11, e34711.	0.5	1
171	Resolution of Electroconvulsive Therapy Refractory Major Depressive Disorder With Unintentional Hypoglycemic Seizure. Journal of ECT, 2013, 29, e47-e48.	0.3	0
172	Metabolic-Inflammation Aspects of Depression and Cardiovascular Disease. , 2016, , 211-233.		0
173	Physical health and metabolic dysfunction in bipolar disorder. , 2016, , 256-268.		0
174	Management Commentary. , 2019, , 263-267.		0
175	Novel therapeutic drug targets for bipolar disorder. , 2021, , 393-404.		0
176	Immunity as a Common Risk Pathway for Psychiatric and Medical Comorbidity. , 2021, , 41-50.		0
177	The neurodevelopmental basis of bipolar disorder: Mechanisms and implications. , 2021, , 11-21.		0
178	Psychopharmacologic Management of Anxiety and Depression. , 2017, , .		0